January 18, 2012 — Topline results of a phase 3 trial of dimebon, also called latrepirdine, on top of ongoing treatment with donepezil has shown no benefit in patients with mild to moderate Alzheimer’s disease (AD). The companies developing dimebon in this indication, Medivation Inc and Pfizer Inc, issued a joint statement noting that results [...]
7.13.2010 Texas Researchers Announce Breakthrough In Alzheimer's Research New Procedure Allows Diagnosis with Simple Blood Test
4.09.2010 TARC Distinguished Speakers Announced For the First Ever “Meeting of the Minds” - The Texas State Plan on Alzheimer’s Disease Public Input Meeting & Scientific Symposium
9.28.2009 Texas Researcher to Receive First International Medal for Scientific Achievement in Neurology
10.09.2009 TARC Alzheimer's Research Director in Lubbock Selected for National Academy of Neuropsychology's Early Career Award
9.21.2009 World Alzheimer Report Projects Alzheimer's, Dementia Will Nearly Double Every 20 Years
4.20.2009 Texas Senate Honors Justice Sandra Day O’Connor for Her Contributions to Expanding Alzheimer’s Research; Texas Alzheimer’s Research Consortium Adds Fifth Institution to Expand Reach to South Texas … Announces New Research Focus on Hispanics Press Release
8.19.2008 Texas Alzheimer's Research Consortium Breaks New Ground in Identifying the Stages of Dementia Progression Press release
03.18.2008 Ten Million U.S. Baby Boomers Projected to Develop Alzheimer's Disease Press Release
03.21.2007 Alzheimer's Cases Expected to Increase 26% in Texas by 2010 Press release DOWNLOAD PDF